Covalon Technologies Ltd. (TSXV:COV)

Market Cap	46.88M
Revenue (ttm)	32.82M
Net Income (ttm)	2.06M
Shares Out	27.42M
EPS (ttm)	0.07
PE Ratio	24.43
Forward PE	14.25
Dividend	0.15 (8.77%)
Ex-Dividend Date	Nov 4, 2025

Volume	15,700
Average Volume	14,939
Open	1.760
Previous Close	1.730
Day's Range	1.680 - 1.760
52-Week Range	1.680 - 3.650
Beta	-0.23
RSI	28.85
Earnings Date	Dec 11, 2025

About Covalon Technologies

Covalon Technologies Ltd. engages in the research, development, manufacturing, and marketing of medical products in infection management, advanced wound care, and surgical procedure areas in the United States, the Middle East, Canada, Latin America, Asia, and internationally. The company’s platform technologies comprises collagen matrix platform that is used to manufacture a family of products to treat chronic and infected wounds, including diabetic ulcers, pressure ulcers, venous ulcers, donor and graft sites, traumatic wounds healing by secon...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2004
• Employees: 37
• Stock Exchange: TSX Venture Exchange
• Ticker Symbol: COV

Financial Performance

In 2025, Covalon Technologies's revenue was 32.82 million, an increase of 5.29% compared to the previous year's 31.17 million. Earnings were 2.06 million, a decrease of -22.91%.